Harrow’s Q1 2026: A VEVYE-Fueled Revenue Story with a Gross-to-Net Twist

Why this quarter matters at a glance

Harrow (Nasdaq: HROW) reported results for the first quarter ended March 31, 2026, with revenue of $44.2 million. A non-recurring gross-to-net adjustment tied to VEVYE’s new commercial coverage reduced reported Q1 revenue by about $8 million, underscoring the ongoing impact of pricing and coverage rules on top-line figures. The balance sheet shows $94.6 million in cash and cash equivalents as of March 31, 2026, a reminder that the company has liquidity to weather the transition under its new reimbursement framework.

The company reaffirmed its 2026 revenue forecast of $350 million to $365 million, signaling management’s confidence that the forward direction remains intact despite the near-term gross-to-net volatility. The quarter’s other data points—strong VEVYE demand, continued growth in TRIESENCE and IHEEZO units, and a robust outlook for Q2—help explain why Harrow’s management remains committed to the structural narrative around its portfolio.

Product momentum and the quarterly mix

• VEVYE delivered record new and total prescription performance, even as the overall branded dry eye category faced an estimated ~18% decline. This juxtaposition illustrates a product-specific strength in the Harrow line that could translate into outsized revenue if coverage expansions hold.
• VEVYE demand growth is on track to push 2026 revenue above $100 million, a milestone that would anchor the company’s back-half performance and raise the bar for the rest of the portfolio.
• Quarterly revenue for Q1 was $44.2 million, with the $8 million gross-to-net adjustment tied to new VEVYE coverage dampening reported results—hinting at a staged earnings impact rather than a permanent margin shift.
• IHEEZO unit demand rose 18% year over year, with 82% of units sourced from retina accounts, underscoring a targeted adoption dynamic among a high-value customer segment.
• TRIESENCE unit demand more than doubled year over year, marking the sixth consecutive quarter of growth, a sign of ongoing market traction for the platform.
• Second quarter revenue guidance is set between $71 million and $81 million, indicating continued cadence in top-line momentum even as the gross-to-net mechanics evolve.

Management view: demand, coverage, and the path to Q2

CEO Mark L. Baum framed the demand backdrop as unusually resilient: “The demand for Harrow’s key products has never been stronger, and our visibility into our demand trajectory—across our portfolio—keeps us entirely on track to reach our forecasted financial goals for the year.” He acknowledged a near-term gross-to-net pressure tied to the VEVYE coverage rollout, calling it a temporary effect that was addressed through new business rules. With those rules in place, management expects the full financial benefits of the expanded commercial access to begin in Q2 2026.

Baum’s commentary also touched on the dynamic of payor behavior and patient-level access. Before the quarter, Harrow established pricing and coverage assumptions for the new VEVYE commercial cohort; as the period unfolded, higher-than-expected demand among patients with high-deductible plans created pressures on gross-to-net accounting. The company contends these pressures are now being mitigated through policy adjustments, and early net-pricing indicators look encouraging as the second quarter unfolds.

What this implies for Harrow and peers

From a finance writer’s perch, the central question is whether the Q1 gross-to-net drag is a one-off fluke or a recurring feature in the new coverage environment. The $8 million adjustment, while material to quarterly results, doesn’t alter the longer-run trajectory of the VEVYE product line, which is the primary engine behind the revenue forecast lift beyond $100 million for that product alone. If pricing discipline and coverage rules stabilize, Harrow could see a meaningful uplift in gross margin and a cleaner path to the mid-single-digit EPS contributions embedded in its plan—though the EPS figure for the quarter isn’t disclosed in the press release, leaving Street consensus to stand in for the moment.

For sector peers, two takeaways loom large. First, payer policy and high-deductible plan dynamics are increasingly shaping reported revenue, not just net income. Second, the market will reward visible demand strength and clear, credible paths to revenue forecast milestones, even when near-term line items—like gross-to-net as a lever—temporarily distort the headline numbers. The balance sheet’s liquidity cushion also matters; with nearly $95 million of cash on hand, Harrow has runway to navigate the transition while investing in growth initiatives.

Outlook: what to watch next

The 2026 revenue guidance of $350–$365 million remains the anchor. The company’s second-quarter target of $71–$81 million and the expectation that VEVYE’s coverage benefits will materialize in Q2 add an element of optionality to the earnings narrative that investors tend to reward—provided the EPS trajectory follows the revenue path. In the near term, investors will parse two numbers: the scale of the gross-to-net adjustment’s normalization and the pace at which IHEEZO and TRIESENCE contribute to sustained top-line growth.

Analysts will likely look for a clean EPS figure in subsequent releases or at least an EPS consensus estimate to anchor expectations. The absence of an explicit EPS number in this release doesn’t derail the strategic impulse—the revenue forecast remains the marquee metric, with the potential for an earnings surprise if gross-to-net dynamics resolve faster-than-expected and pricing indicators strengthen into Q3.

Bottom line

Harrow’s Q1 2026 narrative is a study in product-driven resilience meeting the messy realities of payer economics. The VEVYE-driven growth story sits atop a foundation of expanding unit demand for IHEEZO and TRIESENCE, even as the company works through a one-off gross-to-net adjustment tied to new coverage. If the Q2 wind shifts toward tangible gross-to-net normalization and pricing leverage, the 2026 revenue forecast could translate into a more durable earnings trajectory for Harrow and a benchmark for peers navigating the same reimbursement landscape.